제네릭 의약품 위탁 제조 시장 규모, 점유율, 동향 분석 보고서 : 의약품 유형별, 제품 유형별, 투여 경로별, 용도별, 지역별, 부문별 예측, (2025-2030년)

Generic Pharmaceuticals Contract Manufacturing Market Size, Share & Trends Analysis Report By Drug Type (Branded, Unbranded), By Product (API, Drug Product), By Route Of Administration, By Application, By Region, And Segment Forecasts, 2025 - 2030

US $ 5,950 ￦ 8,609,000

Unprintable PDF (Single User License)

PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 불가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 6,950 ￦ 10,055,000

Printable PDF (5-User License)

PDF 보고서를 동일 기업의 5명까지 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

US $ 8,950 ￦ 12,949,000

Printable PDF (Enterprise License)

PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.

한글목차

제네릭 의약품 위탁 제조 시장의 성장 및 동향

Grand View Research, Inc.의 최신 보고서에 따르면 세계의 제네릭 의약품 위탁 제조 시장 규모는 2030년에는 909억 5,000만 달러에 달할 것으로 예측되고, 2025-2030년에 걸쳐 CAGR 9.98%로 성장할 전망입니다.

아웃소싱 구현과 관련된 비용 절감 및 시간 절약 혜택이 업계를 주도하고 있습니다. 전 세계적으로 상당수의 사람들이 만성 질환으로 고통받고 있습니다.

이것은 제네릭 의약품 제조에 긍정적인 영향을 미쳐 업계 성장에 도움이 될 것으로 기대됩니다. 일본 정부는 일본 내 제네릭 의약품 시장을 개선하기 위해 지속적으로 노력하고 있습니다.

이는 향후 몇 년 동안 제네릭 의약품에 대한 CMO 활동을 개선할 것으로 예상됩니다. 2020년 의약품에 대한 전 세계 지출은 1조 2,650억 달러였으며 2025년에는 1조 5,800억-1조 6,100억 달러에 달할 것으로 예상됩니다. 이는 또한 비용 효율성으로 인해 제네릭 의약품에 대한 수요를 개선하여 업계의 성장을 지원할 것으로 예상됩니다.

제네릭 의약품 위탁 제조 시장 보고서 하이라이트

• 의약품 유형별로, 시장은 브랜드 제네릭과 비브랜드 제네릭으로 구분됩니다.
• 제품별로 시장은 API와 의약품으로 구분됩니다. API 부문은 2024년 가장 큰 시장 점유율을 차지했습니다.
• 투여 경로별로는 시장은 경구, 비경구, 국소, 기타에 구분됩니다.
• 용도별로는 종양학, 면역학, 항당뇨, 신경학, 항응고제, 심혈관, 호흡기, 통증, HIV 항바이러스제 등의 시장이 포함됩니다.
• 2024년 시장 점유율은 북미가 38.90%로 최대였습니다.

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 제네릭 의약품 위탁 제조 시장의 변수, 동향, 범위

• 시장 계통의 전망
  • 상위 시장 전망
  • 관련 및 하위 시장 전망
• 시장 역학
  • 시장 성장 촉진요인 분석
  • 시장 성장 억제요인 분석
• 기술의 진보
• 총 임상시험 규모(2024년)
  • 지역별 총 임상시험 규모
  • 임상시험의 총 규모, 단계별
  • 총 임상시험 수(용도별)
• 가격 모델 분석
• 시장 분석 도구
  • 포터의 5가지 분석
  • SWOT 분석에 의한 PESTEL
  • COVID-19의 영향 분석

제4장 제네릭 의약품 위탁 제조 시장 : 의약품 유형별, 추정 및 동향 분석

• 제네릭 의약품 위탁 제조 시장(의약품 유형별) : 부문 대시보드
• 제네릭 의약품 위탁 제조 시장(의약품 유형별) : 변동 분석
• 의약품 유형별(2018년, 2030년)
• 브랜드 제네릭
• 비브랜드 제네릭

제5장 제네릭 의약품 위탁 제조 시장 : 제품별, 추정 및 동향 분석

• 제네릭 의약품 위탁 제조 시장(제품별 : 부문 대시보드)
• 제네릭 의약품 위탁 제조 시장(제품별 : 변동 분석)
• 제품별(2018년, 2030년)
• API
• 의약품

제6장 제네릭 의약품 위탁 제조 시장 : 투여 경로별, 추정 및 동향 분석

• 제네릭 의약품 위탁 제조 시장(투여 경로별) : 부문 대시보드
• 제네릭 의약품 위탁 제조 시장(투여 경로별) : 변동 분석
• 투여 경로별(2018년, 2030년)
• 경구
• 비경구
• 국소
• 기타

제7장 제네릭 의약품 위탁 제조 시장 : 용도별, 추정 및 동향 분석

• 제네릭 의약품 위탁 제조 시장(용도별) : 부문 대시보드
• 제네릭 의약품 위탁 제조 시장(용도별) : 변동 분석
• 용도별(2018년, 2030년)
• 종양학
• 면역학
• 항당뇨
• 신경학
• 항응고제
• 심혈관
• 호흡기
• 통증
• HIV 항바이러스
• 기타

제8장 제네릭 의약품 위탁 제조 시장 : 지역별, 추정 및 동향 분석

• 지역별 시장 점유율 분석(2024년, 2030년)
• 지역별 시장 대시보드
• 세계 지역 시장 현황
• 북미
  • 미국
  • 캐나다
  • 멕시코
• 유럽
  • 영국
  • 독일
  • 프랑스
  • 이탈리아
  • 스페인
  • 덴마크
  • 스웨덴
  • 노르웨이
• 아시아태평양
  • 일본
  • 중국
  • 인도
  • 태국
  • 한국
  • 호주
• 라틴아메리카
  • 브라질
  • 아르헨티나
• 중동 및 아프리카
  • 남아프리카
  • 사우디아라비아
  • 아랍에미리트(UAE)
  • 쿠웨이트

제9장 경쟁 구도

• 시장 진출기업의 분류
• 기업의 시장 점유율 분석(2024년)
• 기업 프로파일
  • The Lubrizol Corporation
  • Jubilant Generics Ltd.
  • Recipharm AB
  • Siegfried Holding AG
  • Aurobindo Pharma
  • Cambrex Corp.
  • Alcami Corp., Inc.
  • Catalent, Inc.
  • Acme Generics Pvt Ltd.
  • Syngene International Ltd.
  • Pfizer CentreOne
  • Curia Global, Inc.
  • Metric Contract Services

HBR

영문 목차

영문목차

Generic Pharmaceuticals Contract Manufacturing Market Growth & Trends:

The global generic pharmaceuticals contract manufacturing market size is expected to reach USD 90.95 billion by 2030, registering a CAGR of 9.98% from 2025 to 2030, according to a new report by Grand View Research, Inc. Cost-saving and time-saving benefits associated with the implementation of outsourcing is responsible for driving the industry. A significant number of people globally suffer from chronic diseases. For instance, the CDC states that 6 in 10 adults in the U.S. suffer from at least one chronic disease and 4 in 10 adults suffer from two or more chronic diseases. Chronic diseases are required to be treated for a long time. The high cost of medicines is increasing the demand for cost-effective generic drugs for the treatment of chronic diseases.

This is expected to support the industry's growth post-pandemic. There is an improvement in the regulatory approval of generic drugs. For instance, in 2021, the FDA approved 93 generic drugs, and by October 2022, the regulatory authority approved over 95 generic drugs. Such improvements are expected to have a positive impact on the manufacturing of generic drugs and; thus, support the industry growth. The Japanese government is constantly trying to improve the generic pharmaceuticals market in the country. The government is also taking measures to improve the supply of generics in the country and is also encouraging medical institutes to promote the use of generic drugs.

This is expected to improve CMO activities for generics in the coming years. Global spending on medicines is also on the rise. According to the data provided in a report published by IQVIA in April 2021, global spending on medicine is expected to increase in the next 4-5 years. The report states that global spending on medicine accounted for USD 1, 265 billion in 2020 and is going to reach USD 1,580-1,610 billion by 2025. This is also expected to improve the demand for generic drugs owing to their cost efficiency, thereby supporting the industry in growth.

Generic Pharmaceuticals Contract Manufacturing Market Report Highlights:

• On the basis of drug type segment, the market is segmented into branded generics, and unbranded generics. In 2024, the branded generics segment dominated the market, accounting for a revenue share of 59.40%.
• On the basis of the product segment, the market is segmented to API, and Drug Product. API segment accounted for the largest market share in 2024.
• On the basis of route of administration segment, the market includes oral, parenteral, topical, and others. In 2024, the oral segment dominated the market, accounting for a revenue share of 63.73%.
• On the basis of application segment, the market includes oncology, immunology, antidiabetic, neurology, anticoagulants, cardiovascular, respiratory, pain, HIV antivirals, and others.
• North America accounted for the largest market share of 38.90% in 2024. This can be attributed to the growth of the pharmaceutical industries in the U.S. and Canada.

Table of Contents

Chapter 1. Research Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
• 1.3. Research Methodology
• 1.4. Information Procurement
  • 1.4.1. Purchased Database
  • 1.4.2. GVR's Internal Database
  • 1.4.3. Secondary Sources
  • 1.4.4. Primary Research
• 1.5. Information Or Data Analysis
  • 1.5.1. Data Analysis Models
• 1.6. Market Formulation & Validation
• 1.7. Model Details
  • 1.7.1. Commodity Flow Analysis
  • 1.7.2. Parent Market Analysis
• 1.8. List Of Secondary Sources
• 1.9. List Of Abbreviations
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Outlook
• 2.2. Segment Outlook
• 2.3. Competitive Insights

Chapter 3. Generic Pharmaceuticals Contract Manufacturing Market Variables, Trends & Scope

• 3.1. Market Lineage Outlook
  • 3.1.1. Parent Market Outlook
  • 3.1.2. Related/Ancillary Market Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Technological Advancements
• 3.4. Total volume of clinical trials (2024)
  • 3.4.1. Total volume of clinical trials, by region
  • 3.4.2. Total volume of clinical trials, by phase
  • 3.4.3. Total volume of clinical trials, by application
• 3.5. Pricing Model Analysis
• 3.6. Market Analysis Tools
  • 3.6.1. Porter's Five Analysis
  • 3.6.2. PESTEL by SWOT Analysis
  • 3.6.3. COVID-19 Impact Analysis

Chapter 4. Generic Pharmaceuticals Contract Manufacturing Market: Drug Type Estimates & Trend Analysis

• 4.1. Generic Pharmaceuticals Contract Manufacturing Market, By Drug Type: Segment Dashboard
• 4.2. Generic Pharmaceuticals Contract Manufacturing Market, By Drug Type: Movement Analysis
• 4.3. Generic Pharmaceuticals Contract Manufacturing Market Estimates & Forecasts, By Drug Type, 2018 - 2030
• 4.4. Branded Generics
  • 4.4.1. Branded Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 4.5. Unbranded Generics
  • 4.5.1. Unbranded Generics Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Generic Pharmaceuticals Contract Manufacturing Market: Product Estimates & Trend Analysis

• 5.1. Generic Pharmaceuticals Contract Manufacturing Market, By Product: Segment Dashboard
• 5.2. Generic Pharmaceuticals Contract Manufacturing Market, By Product: Movement Analysis
• 5.3. Generic Pharmaceuticals Contract Manufacturing Market Estimates & Forecasts, By Product, 2018 - 2030
• 5.4. API
  • 5.4.1. API Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 5.5. Drug Product
  • 5.5.1. Drug Product Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Generic Pharmaceuticals Contract Manufacturing Market: Route of Administration Estimates & Trend Analysis

• 6.1. Generic Pharmaceuticals Contract Manufacturing Market, By Route of Administration: Segment Dashboard
• 6.2. Generic Pharmaceuticals Contract Manufacturing Market, By Route of Administration: Movement Analysis
• 6.3. Generic Pharmaceuticals Contract Manufacturing Market Estimates & Forecasts, By Route of Administration, 2018 - 2030
• 6.4. Oral
  • 6.4.1. Oral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.5. Parenteral
  • 6.5.1. Parenteral Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.6. Topical
  • 6.6.1. Topical Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 6.7. Others
  • 6.7.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Generic Pharmaceuticals Contract Manufacturing Market: Application Estimates & Trend Analysis

• 7.1. Generic Pharmaceuticals Contract Manufacturing Market, By Application: Segment Dashboard
• 7.2. Generic Pharmaceuticals Contract Manufacturing Market, By Application: Movement Analysis
• 7.3. Generic Pharmaceuticals Contract Manufacturing Market Estimates & Forecasts, By Application, 2018 - 2030
• 7.4. Oncology
  • 7.4.1. Oncology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.5. Immunology
  • 7.5.1. Immunology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.6. Antidiabetic
  • 7.6.1. Antidiabetic Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.7. Neurology
  • 7.7.1. Neurology Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.8. Anticoagulants
  • 7.8.1. Anticoagulants Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.9. Cardiovascular
  • 7.9.1. Cardiovascular Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.10. Respiratory
  • 7.10.1. Respiratory Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.11. Pain
  • 7.11.1. Pain Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.12. HIV Antivirals
  • 7.12.1. HIV Antivirals Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
• 7.13. Others
  • 7.13.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 8. Generic Pharmaceuticals Contract Manufacturing Market: Regional Estimates & Trend Analysis

• 8.1. Regional Market Share Analysis, 2024 & 2030
• 8.2. Regional Market Dashboard
• 8.3. Global Regional Market Snapshot
• 8.4. North America
  • 8.4.1. North America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.2. U.S
    • 8.4.2.1. Key Country Dynamics
    • 8.4.2.2. Competitive Scenario
    • 8.4.2.3. Regulatory Framework
    • 8.4.2.4. U.S. Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.3. Canada
    • 8.4.3.1. Key Country Dynamics
    • 8.4.3.2. Competitive Scenario
    • 8.4.3.3. Regulatory Framework
    • 8.4.3.4. Canada Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.4.4. Mexico
    • 8.4.4.1. Key Country Dynamics
    • 8.4.4.2. Competitive Scenario
    • 8.4.4.3. Regulatory Framework
    • 8.4.4.4. Mexico Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.5. Europe
  • 8.5.1. Europe Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.2. UK
    • 8.5.2.1. Key Country Dynamics
    • 8.5.2.2. Competitive Scenario
    • 8.5.2.3. Regulatory Framework
    • 8.5.2.4. UK Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.3. Germany
    • 8.5.3.1. Key Country Dynamics
    • 8.5.3.2. Competitive Scenario
    • 8.5.3.3. Regulatory Framework
    • 8.5.3.4. Germany Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.4. France
    • 8.5.4.1. Key Country Dynamics
    • 8.5.4.2. Competitive Scenario
    • 8.5.4.3. Regulatory Framework
    • 8.5.4.4. France Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.5. Italy
    • 8.5.5.1. Key Country Dynamics
    • 8.5.5.2. Competitive Scenario
    • 8.5.5.3. Regulatory Framework
    • 8.5.5.4. Italy Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.6. Spain
    • 8.5.6.1. Key Country Dynamics
    • 8.5.6.2. Competitive Scenario
    • 8.5.6.3. Regulatory Framework
    • 8.5.6.4. Spain Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.7. Denmark
    • 8.5.7.1. Key Country Dynamics
    • 8.5.7.2. Competitive Scenario
    • 8.5.7.3. Regulatory Framework
    • 8.5.7.4. Denmark Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.8. Sweden
    • 8.5.8.1. Key Country Dynamics
    • 8.5.8.2. Competitive Scenario
    • 8.5.8.3. Regulatory Framework
    • 8.5.8.4. Sweden Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.5.9. Norway
    • 8.5.9.1. Key Country Dynamics
    • 8.5.9.2. Competitive Scenario
    • 8.5.9.3. Regulatory Framework
    • 8.5.9.4. Norway Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.6. Asia Pacific
  • 8.6.1. Asia Pacific Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.2. Japan
    • 8.6.2.1. Key Country Dynamics
    • 8.6.2.2. Competitive Scenario
    • 8.6.2.3. Regulatory Framework
    • 8.6.2.4. Japan Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.3. China
    • 8.6.3.1. Key Country Dynamics
    • 8.6.3.2. Competitive Scenario
    • 8.6.3.3. Regulatory Framework
    • 8.6.3.4. China Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.4. India
    • 8.6.4.1. Key Country Dynamics
    • 8.6.4.2. Competitive Scenario
    • 8.6.4.3. Regulatory Framework
    • 8.6.4.4. India Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.5. Thailand
    • 8.6.5.1. Key Country Dynamics
    • 8.6.5.2. Competitive Scenario
    • 8.6.5.3. Regulatory Framework
    • 8.6.5.4. Thailand Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.6. South Korea
    • 8.6.6.1. Key Country Dynamics
    • 8.6.6.2. Competitive Scenario
    • 8.6.6.3. Regulatory Framework
    • 8.6.6.4. South Korea Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.6.7. Australia
    • 8.6.7.1. Key Country Dynamics
    • 8.6.7.2. Competitive Scenario
    • 8.6.7.3. Regulatory Framework
    • 8.6.7.4. Australia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.7. Latin America
  • 8.7.1. Latin America Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.2. Brazil
    • 8.7.2.1. Key Country Dynamics
    • 8.7.2.2. Competitive Scenario
    • 8.7.2.3. Regulatory Framework
    • 8.7.2.4. Brazil Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.7.3. Argentina
    • 8.7.3.1. Key Country Dynamics
    • 8.7.3.2. Competitive Scenario
    • 8.7.3.3. Regulatory Framework
    • 8.7.3.4. Argentina Market Estimates and Forecasts, 2018 - 2030 (USD Million)
• 8.8. MEA
  • 8.8.1. MEA Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.2. South Africa
    • 8.8.2.1. Key Country Dynamics
    • 8.8.2.2. Competitive Scenario
    • 8.8.2.3. Regulatory Framework
    • 8.8.2.4. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.3. Saudi Arabia
    • 8.8.3.1. Key Country Dynamics
    • 8.8.3.2. Competitive Scenario
    • 8.8.3.3. Regulatory Framework
    • 8.8.3.4. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.4. UAE
    • 8.8.4.1. Key Country Dynamics
    • 8.8.4.2. Competitive Scenario
    • 8.8.4.3. Regulatory Framework
    • 8.8.4.4. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 8.8.5. Kuwait
    • 8.8.5.1. Key Country Dynamics
    • 8.8.5.2. Competitive Scenario
    • 8.8.5.3. Regulatory Framework
    • 8.8.5.4. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 9. Competitive Landscape

• 9.1. Market Participant Categorization
• 9.2. Company Market Share Analysis, 2024
• 9.3. Company Profiles
  • 9.3.1. The Lubrizol Corporation
    • 9.3.1.1. Company Overview
    • 9.3.1.2. Financial Performance
    • 9.3.1.3. Service Benchmarking
    • 9.3.1.4. Strategic Initiatives
  • 9.3.2. Jubilant Generics Ltd.
    • 9.3.2.1. Company Overview
    • 9.3.2.2. Financial Performance
    • 9.3.2.3. Service Benchmarking
    • 9.3.2.4. Strategic Initiatives
  • 9.3.3. Recipharm AB
    • 9.3.3.1. Company Overview
    • 9.3.3.2. Financial Performance
    • 9.3.3.3. Service Benchmarking
    • 9.3.3.4. Strategic Initiatives
  • 9.3.4. Siegfried Holding AG
    • 9.3.4.1. Company Overview
    • 9.3.4.2. Financial Performance
    • 9.3.4.3. Service Benchmarking
    • 9.3.4.4. Strategic Initiatives
  • 9.3.5. Aurobindo Pharma
    • 9.3.5.1. Company Overview
    • 9.3.5.2. Financial Performance
    • 9.3.5.3. Service Benchmarking
    • 9.3.5.4. Strategic Initiatives
  • 9.3.6. Cambrex Corp.
    • 9.3.6.1. Company Overview
    • 9.3.6.2. Financial Performance
    • 9.3.6.3. Service Benchmarking
    • 9.3.6.4. Strategic Initiatives
  • 9.3.7. Alcami Corp., Inc.
    • 9.3.7.1. Company Overview
    • 9.3.7.2. Financial Performance
    • 9.3.7.3. Service Benchmarking
    • 9.3.7.4. Strategic Initiatives
  • 9.3.8. Catalent, Inc.
    • 9.3.8.1. Company Overview
    • 9.3.8.2. Financial Performance
    • 9.3.8.3. Service Benchmarking
    • 9.3.8.4. Strategic Initiatives
  • 9.3.9. Acme Generics Pvt Ltd.
    • 9.3.9.1. Company Overview
    • 9.3.9.2. Financial Performance
    • 9.3.9.3. Service Benchmarking
    • 9.3.9.4. Strategic Initiatives
  • 9.3.10. Syngene International Ltd.
    • 9.3.10.1. Company Overview
    • 9.3.10.2. Financial Performance
    • 9.3.10.3. Service Benchmarking
    • 9.3.10.4. Strategic Initiatives
  • 9.3.11. Pfizer CentreOne
    • 9.3.11.1. Company Overview
    • 9.3.11.2. Financial Performance
    • 9.3.11.3. Service Benchmarking
    • 9.3.11.4. Strategic Initiatives
  • 9.3.12. Curia Global, Inc.
    • 9.3.12.1. Company Overview
    • 9.3.12.2. Financial Performance
    • 9.3.12.3. Service Benchmarking
    • 9.3.12.4. Strategic Initiatives
  • 9.3.13. Metric Contract Services
    • 9.3.13.1. Company Overview
    • 9.3.13.2. Financial Performance
    • 9.3.13.3. Service Benchmarking
    • 9.3.13.4. Strategic Initiatives

관련자료